LXRX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Lexicon Pharmaceuticals, Inc. had $49.8M of revenue in fiscal 2025, up 60.2% on the year before. Over five years, revenue changed +15.7% a year on average.
Last close Β· Oct 23, 2026
$1.42
4.7%Hi! I read Lexicon Pharmaceuticals, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+60.2%
Yes. Sales grew 60.2% last year.
Does it make a profit?
β101.1%
No. It lost money last year.
Does profit turn into cash?
β136.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Lexicon Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 7, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 29, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 6, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 6, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 6, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Lexicon Pharmaceuticals, Inc. had $49.8M of revenue in fiscal 2025, up 60.2% on the year before. Over five years, revenue changed +15.7% a year on average. Its operating margin was β98.2%, up 536.0Β pts: of every 100 in sales, about β98 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Lexicon Pharmaceuticals, Inc. lost $50.3M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$67.9M in fiscal 2025, β136.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Lexicon Pharmaceuticals, Inc. has $42.2M more cash than debt.
Cash, debt and the ratios that show how comfortably Lexicon Pharmaceuticals, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $86.7M | $138M | $170M | $238M | $96.2M |
| Debt incl. finance leases | $0.0M | $48.6M | $99.5M | $100M | $54.0M |
| Debt / equity | 0.0x | 0.4x | 1.1x | 0.7x | 0.5x |
| Interest coverage | β108.6x | β36.2x | β | β | β |
| Current ratio | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Quick ratio | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Total assets | $137M | $194M | $229M | $298M | $185M |
| Total liabilities | $23.3M | $77.2M | $136M | $152M | $77.4M |
| Shareholders' equity | $114M | $117M | $93.1M | $146M | $108M |
| Net debt (β = net cash) | β$86.7M | β$89.8M | β$70.5M | β$138M | β$42.2M |
KIRA Β· Its return on capital was β59.2%: every 100 invested in the business earned about β59 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Lexicon Pharmaceuticals, Inc. passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 2 / 9 | 7 / 9 | 2 / 9 | 4 / 9 | 3 / 9 | 2 / 9 | 5 / 9 | 4 / 9 |
| Accruals ratio | 9.3% | 13.7% | 7.8% | 4.7% | 27.2% | β0.4% | β7.9% | β7.2% | β8.2% | 7.2% |
| Altman Z'' | β7.15 | β8.76 | β16.26 | β3.51 | β16.94 | β31.38 | β24.59 | β25.27 | β20.51 | β33.00 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $79.3M | $91.7M | $63.2M | $322M | $24.0M | $0.3M | $0.1M | $1.2M | $31.1M | $49.8M |
| Gross profit | $79.3M | $89.8M | $60.7M | $319M | $22.1M | $0.3M | $0.1M | $1.1M | $30.5M | $49.5M |
| Research and development | $164M | $152M | $100M | $91.9M | $154M | $55.0M | $52.8M | $58.9M | $84.5M | $61.1M |
| Operating income | β$127M | β$131M | β$103M | $141M | β$47.8M | β$87.1M | β$101M | β$172M | β$197M | β$48.9M |
| Interest expense | $6.6M | $7.0M | $20.8M | $20.7M | $14.5M | $0.8M | $2.8M | β | β | β |
| Pretax income | β$131M | β$136M | β$121M | $124M | β$58.6M | β$87.8M | β | β | β | β |
| Income tax | $0.0M | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Net income | β$131M | β$123M | β$121M | $130M | β$58.6M | β$87.8M | β$102M | β$177M | β$200M | β$50.3M |
| Diluted EPS | β$1.27 | β$1.17 | β$1.14 | $1.16 | β$0.53 | β$0.60 | β$0.62 | β$0.80 | β$0.63 | β$0.14 |
| Diluted shares | 0.10B | 0.11B | 0.11B | 0.12B | 0.11B | 0.15B | 0.17B | 0.22B | 0.32B | 0.36B |
| Cash flow | ||||||||||
| Cash from operations | β$176M | β$185M | β$149M | $114M | β$143M | β$87.0M | β$88.9M | β$162M | β$179M | β$67.9M |
| Capital expenditure | $0.2M | $0.2M | $0.1M | $0.1M | $0.1M | $1.2M | $1.3M | $0.5M | $1.0M | $0.0M |
| Free cash flow | β$176M | β$186M | β$149M | $114M | β$143M | β$88.2M | β$90.2M | β$162M | β$180M | β$67.9M |
| Depreciation and amortization | $2.1M | $3.4M | $3.7M | $3.7M | $2.9M | $0.3M | $0.4M | $0.6M | $0.5M | $0.6M |
| Stock-based compensation | $7.5M | $9.5M | $11.7M | $14.2M | $13.3M | $10.6M | $11.5M | $14.3M | $13.5M | $12.5M |
| Share buybacks | $0.6M | $1.7M | $1.0M | $0.9M | $1.0M | $2.7M | $0.9M | $0.8M | $1.7M | β |
| Dividends and buybacks | $0.6M | $1.7M | $1.0M | $0.9M | $1.0M | $2.7M | $0.9M | $0.8M | $1.7M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $347M | $311M | $160M | $272M | $152M | $86.7M | $138M | $170M | $238M | $96.2M |
| Total debt | $101M | $252M | $250M | $249M | $11.6M | $0.0M | $48.6M | $99.5M | $100M | $54.0M |
| Current assets | $358M | $322M | $173M | $338M | $158M | $88.9M | $141M | $177M | $246M | $102M |
| Current liabilities | $165M | $105M | $36.8M | $65.3M | $46.8M | $22.1M | $23.2M | $31.5M | $45.2M | $20.9M |
| Inventory | $0.0M | $1.9M | $4.7M | $4.2M | $0.0M | β | $0.0M | $0.4M | $0.2M | $0.3M |
| Property and equipment, net | $19.4M | $17.7M | $15.9M | $14.0M | $0.3M | $1.2M | $2.1M | $2.0M | $2.5M | $1.9M |
| Goodwill | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M |
| Intangible assets | $53.4M | $51.9M | $50.1M | $19.7M | β | β | β | β | β | β |
| Total assets | $476M | $437M | $284M | $418M | $204M | $137M | $194M | $229M | $298M | $185M |
| Total liabilities | $318M | $368M | $311M | $301M | $47.4M | $23.3M | $77.2M | $136M | $152M | $77.4M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $168M | $68.3M | β$26.4M | $117M | $156M | $114M | $117M | $93.1M | $146M | $108M |
| Margins | ||||||||||
| Gross margin | 100.0% | 97.9% | 96.1% | 99.0% | 92.0% | 100.0% | 100.0% | 92.9% | 98.0% | 99.4% |
| Operating margin | β160.5% | β142.5% | β163.4% | 43.9% | β199.2% | β29,224.8% | β72,489.2% | β14,265.0% | β634.2% | β98.2% |
| EBITDA margin | β157.9% | β138.8% | β157.6% | 45.1% | β187.0% | β29,126.8% | β72,182.0% | β14,218.9% | β632.5% | β97.0% |
| Net margin | β165.8% | β134.1% | β190.7% | 40.4% | β244.1% | β29,449.0% | β73,341.0% | β14,710.9% | β644.8% | β101.1% |
| FCF margin | β221.9% | β202.4% | β235.3% | 35.3% | β596.2% | β29,610.1% | β64,875.5% | β13,485.6% | β578.5% | β136.2% |
| Returns | ||||||||||
| Return on capital | β | β1,137.6% | β128.6% | 118.8% | β239.9% | β256.2% | β290.9% | β600.6% | β1,878.2% | β59.2% |
| Return on capital employed | β40.9% | β39.5% | β41.7% | 40.1% | β30.4% | β75.9% | β58.9% | β86.8% | β77.9% | β29.8% |
| Return on equity | β78.5% | β104.3% | β576.0% | 287.0% | β42.8% | β65.0% | β88.4% | β168.5% | β167.7% | β39.7% |
| Return on assets | β27.6% | β27.0% | β33.5% | 37.1% | β18.8% | β51.5% | β61.6% | β83.6% | β75.9% | β20.8% |
| Return on tangible equity | β188.8% | β | β | 246.3% | β52.4% | β127.1% | β140.5% | β364.7% | β197.6% | β79.9% |
| Growth | ||||||||||
| Revenue growth | β | 15.7% | β31.1% | 409.5% | β92.5% | β98.8% | β53.4% | 766.2% | 2,481.5% | 60.2% |
| Net income growth | β | β | β | β | β145.0% | β | β | β | β | β |
| EPS growth | β | β | β | β | β145.7% | β | β | β | β | β |
| FCF growth | β | β | β | β | β225.8% | β | β | β | β | β |
| Share count change | β | 1.3% | 0.6% | 10.3% | β5.1% | 31.4% | 13.8% | 33.4% | 44.7% | 13.4% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β0.2x | β | β | β | β | β | β |
| Debt / equity | 0.6x | 3.7x | β | 2.1x | 0.1x | 0.0x | 0.4x | 1.1x | 0.7x | 0.5x |
| Interest coverage | β19.4x | β18.7x | β5.0x | 6.8x | β3.3x | β108.6x | β36.2x | β | β | β |
| Current ratio | 2.2x | 3.1x | 4.7x | 5.2x | 3.4x | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Quick ratio | 2.2x | 3.0x | 4.6x | 5.1x | 3.4x | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.3% | 0.2% | 0.2% | 0.0% | 0.4% | 409.7% | 954.0% | 39.0% | 3.3% | 0.0% |
| Stock comp / revenue | 9.4% | 10.3% | 18.5% | 4.4% | 55.3% | 3,549.3% | 8,287.8% | 1,191.0% | 43.4% | 25.1% |
| Payouts / FCF | β | β | β | 0.8% | β | β | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 2.0 | 7.0 | 2.0 | 4.0 | 3.0 | 2.0 | 5.0 | 4.0 |
| Altman Z'' | β7.1 | β8.8 | β16.3 | β3.5 | β16.9 | β31.4 | β24.6 | β25.3 | β20.5 | β33.0 |
| Accruals ratio | 9.3% | 13.7% | 7.8% | 4.7% | 27.2% | β0.4% | β7.9% | β7.2% | β8.2% | 7.2% |
Source: SEC EDGAR XBRL filings (CIK 0001062822). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
